about
Dietary Intakes and Nutritional Issues in Neurologically Impaired ChildrenGluten-free diet in children: an approach to a nutritionally adequate and balanced dietThe immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study.Suicide in pediatrics: epidemiology, risk factors, warning signs and the role of the pediatrician in detecting themA longitudinal study of streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine eraNew insights into rotavirus vaccines.Probiotics and atopic dermatitis in children.Influvac, a trivalent inactivated subunit influenza vaccine.Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future.Positional plagiocephaly: what the pediatrician needs to know. A review.The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.Intakes of nutrients in Italian children with celiac disease and the role of commercially available gluten-free products.Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults.Sclerostin and DKK-1: two important regulators of bone metabolism in HIV-infected youths.Hemolytic crisis in a G6PD-deficient infant after ingestion of pumpkin.Indications to respiratory syncytial virus immunoprophylaxis in the 29-32 wGA group: is there still room for debating?Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.Both HIV-infection and long-term antiretroviral therapy are associated with increased common carotid intima-media thickness in HIV-infected adolescents and young adults.Resource utilization and direct costs of pediatric HIV in Italy.Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.Strategies for preventing influenza: future perspectives in influenza vaccine technology.Probiotics: current evidences and new perspectives.Sedentary behaviour as a risk factor for cardiovascular diseases in pediatric age.Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational Study.Neonates born to mothers using antidepressant drugs.A case of worsening lipoatrophy in a 13 year-old girl.Enalapril Associated with Furosemide Induced Acute Kidney Injury in an Infant with Heart Failure. A Case Report, a Revision of the Literature and a Pharmacovigilance Database Analysis.Safety issues with ethanol as an excipient in drugs intended for pediatric use.Fever and ascites underlying abdominal aspergillosis in a 3-year-old boyFermented Rice Flour in Pediatric Atopic DermatitisPerceptions and patterns of use of generic drugs among Italian Family Pediatricians: First round results of a web surveyPaediatric pharmacology: Remember the excipientsLeprosy: A disease not to be forgotten in the era of globalizationGrowth Pattern, Resting Energy Expenditure, and Nutrient Intake of Children with Food AllergiesPaediatricians play a key role in preventing early harmful events that could permanently influence the development of the gut microbiota in childhood
P50
Q28087116-4C6285EE-9535-4BF3-8535-D76C27358FCFQ28302305-5FFD5719-9B8E-4EA2-A522-304535E57B20Q30573058-A27BCECA-254D-45AA-AE8C-A2393191D796Q35828149-FF859827-661F-44BE-BDD1-8CAC41F02BE9Q35887787-482C9A9C-A8D3-4E6A-B3F3-120B84CC1853Q36552854-3F24D7B9-A6C2-4697-A36A-C34E27236A58Q37148768-7B426A06-13E6-45AA-B848-6E76E73CDA86Q37812615-7BB6E4E3-D297-42E3-BEA4-480C409454C9Q37872784-00D00A10-F511-498E-AE45-6D051BF96D13Q37879967-5BD28479-90A6-4B8D-92DA-366CED0EF2E4Q38599522-8AE34838-ACBF-4939-A7E4-1CEDE5DF1D7AQ39500929-5C1F1EB7-9B64-4235-BAE6-BFC81D39AC99Q41350197-56F72940-B584-499C-BD8F-4F1EAB728C53Q41537603-287153CB-6066-4B81-9F26-E1CB30D43FC5Q41864438-AB859055-1014-4141-A206-B24A9524C5AEQ42316805-8F00AE2E-1DE6-4CEF-936A-13F03E05402AQ42839637-4CA8747A-A0E1-4995-9A95-4B03C64FEA10Q43082317-2881E842-75BE-45DA-B315-C7EB652835AAQ44179241-70E0588F-F741-4D04-83CA-66A131714D47Q44677110-0ED68EF5-5AFD-4210-8D34-E1537F83C39CQ44902406-0D297702-E937-461F-843B-002CBC9CC24DQ46103426-7B3B609A-32B4-4A04-8C46-96698274CB13Q46104634-8126A766-F495-4106-A9C5-688ED22270A4Q48001442-42A3DDB2-1B67-4143-AB9F-5B67A3DC89B1Q48673324-B1B5B754-902A-4B10-B6A3-8CD8B309DA72Q49169090-7D960DBD-C1D9-4C49-AE55-E60BE44390BAQ50911754-7BCD51C9-4930-499A-B106-6F687E9F6464Q55054084-9721A7A8-7303-4E4E-ABE3-BAF5C9D9572BQ56321884-E1DE933F-9AA0-44F2-A8F7-DA10EAB97C3FQ57450930-5249F11C-A210-4C9B-8E87-8B7A09BFEFB8Q57451038-27C00ABF-744A-4554-97D6-5BEF46A95096Q57451054-CEFD1C90-E3CA-424E-8EA4-B19CC1AC6454Q57451087-0A5FD5EB-AAD9-4CE5-9411-8520317FC294Q64258584-B44724A3-71D6-49D7-9B63-AFCB7B1A057CQ92738115-02B5ADBA-D960-4F45-90C5-07A3868C4773
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Valentina Fabiano
@ast
Valentina Fabiano
@en
Valentina Fabiano
@es
Valentina Fabiano
@nl
Valentina Fabiano
@sl
type
label
Valentina Fabiano
@ast
Valentina Fabiano
@en
Valentina Fabiano
@es
Valentina Fabiano
@nl
Valentina Fabiano
@sl
prefLabel
Valentina Fabiano
@ast
Valentina Fabiano
@en
Valentina Fabiano
@es
Valentina Fabiano
@nl
Valentina Fabiano
@sl
P1053
H-8818-2017
P106
P1153
36460882900
P21
P31
P3829
P496
0000-0001-6449-1724